Literature DB >> 24656601

Correlation between cerebral microbleeds and S100B/RAGE in acute lacunar stroke patients.

Lulu Xiao1, Wen Sun2, Wenya Lan1, Yunyun Xiong3, Zuowei Duan2, Zongjun Zhang4, Wenping Fan1, Lili Xu1, Xia Xie2, Nan Ma1, Ruidong Ye1, Gelin Xu3, Xinfeng Liu3, Wusheng Zhu5.   

Abstract

BACKGROUND AND
PURPOSE: S100B and its scavenger, soluble receptor for advanced glycation end products (sRAGE), participate in various acute and chronic brain disorders. However, their impact on hemorrhage-prone small vessel disease represented by cerebral microbleeds (CMBs) is unclear. The purpose of this study was to investigate the relationship of CMBs with plasma S100B and sRAGE.
METHODS: A cohort of 147 consecutive patients with first-ever acute lacunar stroke was prospectively enrolled. We collected demographic, clinical, and laboratory data, including plasma levels of S100B and sRAGE, and presence and number of CMBs using susceptibility-weighted imaging (SWI). Associations between plasma S100B, sRAGE levels and the presence, number, and location of CMBs were determined.
RESULTS: CMBs were present in 58 patients (39.5%). Each 1SD-increase in S100B and sRAGE levels was significantly associated with presence of CMBs (adjusted odds ratio [OR], 3.06; 95% confidence interval [CI], 1.81-5.17 and adjusted OR, 0.29; 95% CI, 0.16-0.53; respectively) and number of CMBs (adjusted relative risk [RR], 4.07; 95% CI, 3.60-5.65 for S100B and RR 0.34; 95% CI, 0.25-0.46 for sRAGE). When stratified by location, plasma S100B and sRAGE levels were similarly associated with presence of deep CMBs (adjusted OR, 3.65; 95% CI, 1.99-6.69 and adjusted OR, 0.23; 95% CI, 0.12-0.46; respectively), but not with strictly lobar CMBs.
CONCLUSIONS: Higher levels of S100B and lower levels of sRAGE are independently associated with presence and number of CMBs in patients with first-ever acute lacunar stroke, particularly in those with deep CMBs.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebral microbleeds; Lacunar stroke; S100B; Small vessel disease; Susceptibility-weighted imaging; sRAGE

Mesh:

Substances:

Year:  2014        PMID: 24656601     DOI: 10.1016/j.jns.2014.03.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case-control study.

Authors:  Fei Wang; Zhi-Rong Zou; Dong Yuan; Yi Gong; Li Zhang; Xun Chen; Tao Sun; Hua-Lin Yu
Journal:  Biosci Rep       Date:  2017-04-10       Impact factor: 3.840

Review 2.  Dysfunction of the Blood-brain Barrier in Cerebral Microbleeds: from Bedside to Bench.

Authors:  Hai-Ling Wang; Chun-Lin Zhang; Yan-Mei Qiu; An-Qi Chen; Ya-Nan Li; Bo Hu
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

3.  Lower Serum Caveolin-1 Is Associated with Cerebral Microbleeds in Patients with Acute Ischemic Stroke.

Authors:  Jun Zhang; Wusheng Zhu; Lulu Xiao; Qinqin Cao; Hao Zhang; Huaiming Wang; Zusen Ye; Yonggang Hao; Qiliang Dai; Wen Sun; Yunyun Xiong; Xinfeng Liu; Ruidong Ye; Gelin Xu
Journal:  Oxid Med Cell Longev       Date:  2016-03-28       Impact factor: 6.543

4.  A cohort study of relationship between serum calcium levels and cerebral microbleeds (CMBs) in ischemic stroke patients with AF and/or RHD.

Authors:  Junfeng Liu; Deren Wang; Yao Xiong; Bian Liu; Chenchen Wei; Zhenxing Ma; Bo Wu; Ruozhen Yuan; Hehan Tang; Ming Liu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 5.  The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms.

Authors:  Wei Ling Lau; Branko N Huisa; Mark Fisher
Journal:  Transl Stroke Res       Date:  2016-09-14       Impact factor: 6.829

Review 6.  Biomarkers for acute diagnosis and management of stroke in neurointensive care units.

Authors:  Olena Y Glushakova; Alexander V Glushakov; Emmy R Miller; Alex B Valadka; Ronald L Hayes
Journal:  Brain Circ       Date:  2016-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.